Parallel Advisors, LLC Chemo Centryx, Inc. Transaction History

Parallel Advisors, LLC

$4.18 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $469,649 - $1.1 Million	-21,184 Reduced 99.32%	145 $7,000
Q2 2022 Aug 01, 2022	SELL	$15.36 - $27.51 $168 - $302	-11 Reduced 0.05%	21,329 $529,000
Q1 2022 Apr 28, 2022	BUY	$22.22 - $39.12 $466,620 - $821,520	21,000 Added 6176.47%	21,340 $534,000
Q4 2021 Jan 20, 2022	BUY	$18.38 - $40.5 $2,830 - $6,237	154 Added 82.8%	340 $12,000
Q3 2021 Nov 02, 2021	BUY	$13.18 - $19.83 $2,451 - $3,688	186 New	186 $3,000
Q2 2021 Aug 06, 2021	SELL	$9.59 - $50.88 $335 - $1,780	-35 Closed	0 $0
Q3 2020 Oct 27, 2020	BUY	$46.35 - $61.69 $231 - $308	5 Added 16.67%	35 $2,000
Q2 2020 Jul 16, 2020	BUY	$38.58 - $65.07 $1,157 - $1,952	30 New	30 $1,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.